Device Trial Radar · NCT04337853
Radiotherapy of Tongue Cancer Using an Intraoral Stent
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Mar 9, 2018
Primary completion
Dec 4, 2018
Study completion Dec 4, 2018
Sponsor
- Lead sponsor
- Oslo University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Oslo Metropolitan University
- First posted
- Apr 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Radiotherapy of tongue cancer is associated with acute and late morbidity. Use of an intraoral stent will provide a larger distance between the tongue and palate and can reduce side-effects. The aim of the present study is to confirm that an intraoral stent will give lower dose to the palate throughout the treatment period.
Conditions
- Tongue Cancer
Interventions
Intraoral stentDevice
Radiotherapy with intraoral stent
No intraoral stentOther
Radiotherapy without intraoral stent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction in mean dose to the hard palateTime frame: At the end of radiotherapy (5-6 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Oslo University Hospital
Oslo, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.